<DOC>
	<DOC>NCT01418092</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ALKS 37 when administered daily to adults with OIC.</brief_summary>
	<brief_title>ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Are at least 18 years of age at time of consent Have a body mass index (BMI)of 19 to 35 kg/m2 at screening Are receiving prescribed opioid medication for the management of chronic, noncancer pain Meet the criteria of OIC Agree to use an acceptable method of contraception for the duration of the study Pregnancy and/or currently breastfeeding Clinically significant medical condition or illness (other than the condition for which the pain medication is being prescribed) Receiving treatment with opioid therapy for cancerrelated pain, abdominal pain, scleroderma, and/or for the management of drug addiction Any gastrointestinal (GI) disorder (other than opioidinduced constipation) or GI structural abnormality known to affect bowel transit, produce GI obstruction, or contribute to bowel dysfunction Use of naloxone, Subutex or Suboxone, Revia, Vivitrol, Relistor, or Entereg starting 15 days before the first study visit following screening until the end of the study Participation in a clinical trial of a pharmacological agent within 30 days before screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>